Skip to main content

Bliss GVS Pharma Ltd

Stage 2 · Advancing · week 45Setup 5.1 ★ FairSolid +5.6

As of 16 Oct 2026, Bliss GVS Pharma is in Stage 2 — advancing, the uptrend phase, in week 45 (since 1 Dec 2025). It closed at ₹652, 11.6% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. More about the company

₹652
-0.35% today
₹6,933 Cr · Mid cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

5.1 ★ Fair

Momentum

Steady

Edge

Solid +5.6

Setup-score rank among Stage 2 peers: #19 of 59 in Pharmaceuticals · #23 of 70 in Health Care

Is BLISSGVS early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
vs 52W High
-11.6%
₹127.6 lo₹737.7 hi
11.6% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 45
1w13w26w
Week 45 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
69.1%
200 DMA: ₹385.6 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.34x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -1.7% vs MA50 +14.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-4.2%
3M
+34.9%
6M
+151.8%
YTD
+271.8%
1Y
+329.8%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #1 of 66 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #1 of 56 Stage 2 stocks in this industry. Top stock in industry.
Stage Cycle Timeline2023-07-20 → 2026-10-16
S3 16w
S2 46w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 12w → S3 4w → S2 13w → S3 16w → S4 8w → S1 5w → S2 10w → S3 1w → S2 11w → S3 6w → S4 9w → S1 6w → S2 11w → S3 9w → S2 46w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-16
Pullback Hunter
Latest: 2026-08-10
60 appearances in last 60 days. First seen: 2026-07-27.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 45 · Vol 0.34x
2026-10-15S2
Wk 45 · Vol 0.17x
2026-10-14S2
Wk 45 · Vol 0.19x
2026-10-13S2
Wk 45 · Vol 0.59x
2026-10-12S2
Wk 44 · Vol 0.22x
2026-10-09S2
Wk 44 · Vol 0.40x
2026-10-08S2
Wk 44 · Vol 0.37x
2026-10-07S2
Wk 44 · Vol 0.42x
2026-10-06S2
Wk 44 · Vol 0.42x
2026-10-05S2
Wk 43 · Vol 0.50x
2026-10-01S2
Wk 43 · Vol 0.33x
2026-09-30S2
Wk 43 · Vol 0.52x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹630.2
200 DMA
₹385.6
52W High
₹737.7
52W Low
₹127.6
5D Low
₹652
Resistance levels (recent highs)
20d High
₹737.7
60d High
₹737.7
120d High
₹737.7
250d High
₹737.7
Next resistance
+13.1%
to 20d High
P/E (TTM)
33.1
Forward —
Earnings Growth (YoY)
-5.7%
Revenue +3.7%
Dividend Yield
0.26%
P/B 3.7
About this companyHealth Care· Pharmaceuticals

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.